<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kastritis, Esftathios</style></author><author><style face="normal" font="default" size="100%">Kostopoulos, Ioannis V.</style></author><author><style face="normal" font="default" size="100%">Theodorakakou, Foteini</style></author><author><style face="normal" font="default" size="100%">Fotiou, Despina</style></author><author><style face="normal" font="default" size="100%">Gavriatopoulou, Maria</style></author><author><style face="normal" font="default" size="100%">Migkou, Magdalini</style></author><author><style face="normal" font="default" size="100%">Tselegkidi, Maria Irini</style></author><author><style face="normal" font="default" size="100%">Roussou, Maria</style></author><author><style face="normal" font="default" size="100%">Papathoma, Alexandra</style></author><author><style face="normal" font="default" size="100%">Eleutherakis-Papaioakovou, Evangelos</style></author><author><style face="normal" font="default" size="100%">Dialoupi, Ioanna</style></author><author><style face="normal" font="default" size="100%">Kanellias, Nikolaos</style></author><author><style face="normal" font="default" size="100%">Ntalianis, Argyrios</style></author><author><style face="normal" font="default" size="100%">Rousakis, Pantelis</style></author><author><style face="normal" font="default" size="100%">Trougakos, Ioannis P.</style></author><author><style face="normal" font="default" size="100%">Tsitsilonis, Ourania</style></author><author><style face="normal" font="default" size="100%">Gakiopoulou, Charikleia</style></author><author><style face="normal" font="default" size="100%">Terpos, Evangelos</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, Meletios A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">{Next generation flow cytometry for MRD detection in patients with AL amyloidosis}</style></title><secondary-title><style face="normal" font="default" size="100%">Amyloid</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">EuroFlow</style></keyword><keyword><style  face="normal" font="default" size="100%">free light chains</style></keyword><keyword><style  face="normal" font="default" size="100%">minimal residual disease</style></keyword><keyword><style  face="normal" font="default" size="100%">next generation flow cytometry</style></keyword><keyword><style  face="normal" font="default" size="100%">NTproBNP</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">aug</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://doi.org/10.1080/13506129.2020.1802713 https://www.tandfonline.com/doi/full/10.1080/13506129.2020.1802713</style></url></web-urls></urls><publisher><style face="normal" font="default" size="100%">Taylor {&amp;} Francis</style></publisher><pages><style face="normal" font="default" size="100%">1–5</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The treatment of AL amyloidosis aims to eradicate the plasma cell clone and eliminate toxic free light chain production. Only in a minority of patients the plasma cell clone is completely eradicated; residual light chain production may still exist while clonal relapse may occur. We used sensitive next-generation flow cytometry (NGF) to detect minimal residual disease (MRD) in AL amyloidosis patients at complete haematologic response. MRD evaluation was feasible in 51 of 52 (98{%}) tested patients and at a median sensitivity of 2.3 × 10−6 MRD was undetectable in 23 (45{%}). An organ response occurred in 86{%} of MRDneg vs 77{%} in MRDpos; renal response in 15/17(88{%}) of MRDneg vs in 14/16(87.5{%}) of MRDpos and cardiac response in 10/10(100{%}) of MRDneg vs 11/15(73{%}) of MRDpos patients. After a median follow-up of 24 months post MRD testing, no MRDneg patient had a haematologic relapse vs 6/28(21{%}) MRDpos (p =.029). Pooling haematologic and organ progressions, 9 (32{%}) MRDpos patients had disease progression vs only 1 (4{%}) MRDneg patient (p =.026). In conclusion, MRD detection using NGF has profound clinical implications, so that AL patients with undetectable MRD have a very high probability of organ response and a very low probability of haematologic relapse.</style></abstract></record></records></xml>